Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine
AssigneeTrovagene, Inc.
InventorsHovsep Melkonyan, Angela Cannas, Louis David Tomei, Samuil R. Umansky
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosing and/or monitoring a bacterial or parasitic infection by detection and quantification of the transrenal nucleic acids, derived from bacterial pathogenic agents or from parasites, in urine. The detection method optionally includes the isolation and the purification of the nucleic acids from urine by methods known in the art including pairing with molecular probes that are specific for the pathogenic agents, PCR hybridization, PCR, nested PCR, SSCP, LCR, and SDA. Diagnostic kits based on these detection methods are also claimed.
Claims10
A kit, comprising:
- a) one or more reagents or materials for the isolation and purification of cell-free pathogen-related transrenal nucleic acids from a urine sample of a subject, wherein said reagents or materials comprise a matrix including a silica-based resin, wherein said silica-based resin isolates cell-free nucleic acids that are less than about 300 nucleotides;
- and wherein said reagents or materials comprise an agent that inhibits the degradation of the cell-free nucleic acids;
- and
- b) two or more primers for detecting said cell-free pathogen-related nucleic acids in said urine sample, wherein said two or more primers are selected from the group consisting of SEQ ID NOs:
- 1-3.
A kit, comprising:
- a) one or more reagents or materials for the detection and quantitation of cell-free pathogen-related nucleic acids from a urine sample of a subject, wherein said reagents or materials comprise a matrix including a silica-based resin, wherein said silica-based resin isolates cell-free nucleic acids that are less than about 300 nucleotides;
- and wherein said reagents or materials comprise an agent that inhibits the degradation of the cell-free nucleic acids;
- and
- b) two or more primers for detecting and quantitating said cell-free pathogen-related nucleic acids in said urine sample, wherein said two or more primers are selected from the group consisting of SEQ ID NOs:
- 1-3.
Dependencies are inferred from the claim text.